Detalhe da pesquisa
1.
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
Diabetes Obes Metab
; 25(2): 468-478, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200477
2.
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
Obesity (Silver Spring)
; 31(3): 703-715, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36655300
3.
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials.
EClinicalMedicine
; 55: 101737, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36467859
4.
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Nat Med
; 28(10): 2083-2091, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36216945